TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23328996

Group type: EXPERIMENTAL
Intervention: Docetaxel (30 mg/m²) and cisplatin (30 mg/m²) every week for five cycles plus external radiation (46-54 Gy) followed by high-dose rate brachytherapy (12-24 Gy)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Single-agent cisplatin (40 mg/m²) every week for five cycles plus external radiation (46-54 Gy) followed by high-dose rate brachytherapy (12-24 Gy)
Number of subjects: 285
Study: 19956928

Group type: EXPERIMENTAL
Intervention: BPTB grafts fixed with metal interference screws
Number of subjects: 115

Group type: COMPARATOR
Intervention: DLSG grafts fixed with Bone Mulch Screws and WasherLoc Screws
Number of subjects: 115
Study: 19753397

Group type: EXPERIMENTAL
Intervention: Computer-based instruction (CBI)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Lecture-based instruction
Number of subjects: 62
Study: 16750611

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 40
Study: 12833203

Group type: EXPERIMENTAL
Intervention: NPPV
Number of subjects: 30
Study: 11072806

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 83

Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Pancuronium with PORP
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Pancuronium without PORP
Number of subjects: 83
Study: 8630937

Group type: EXPERIMENTAL
Intervention: 5‐FU infusions plus oral HCFU administration (Group A)
Number of subjects: 269

Group type: COMPARATOR
Intervention: 5‐FU injections (Group B)
Number of subjects: 269
Study: 1558344

Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole (325 mg aspirin, 75 mg dipyridamole, starting 12 hours preoperatively and continuing for 1 year)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo medication identical in appearance to the study drugs
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 2859043

Group type: EXPERIMENTAL
Intervention: 20 mg betaxolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 160 mg propranolol LA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Betaxolol and Atenolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pedometer step counts
Number of subjects: 12
Study: 29855153

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Dexamethasone (0.7 mg implant)
Number of subjects: 175
Study: 26669570

Group type: EXPERIMENTAL
Intervention: Individual dietary counselling session and group dietary counselling session in addition to standard counselling
Number of subjects: 242

Group type: COMPARATOR
Intervention: Standard antenatal dietary counselling according to the Finnish Nutrition Recommendations
Number of subjects: 242
Study: 24646819

Group type: EXPERIMENTAL
Intervention: Probiotic capsule
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 138
Study: 22698597

Group type: EXPERIMENTAL
Intervention: Tricuspid regurgitation treatment (group T)
Number of subjects: 167

Group type: COMPARATOR
Intervention: No tricuspid regurgitation treatment (group no-T)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Tricuspid regurgitation treatment (group T) in subgroup A (TAD/BSA ≤ 21 mm/m2)
Number of subjects: 167

Group type: COMPARATOR
Intervention: No tricuspid regurgitation treatment (group no-T) in subgroup A (TAD/BSA ≤ 21 mm/m2)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Tricuspid valvoplasty (group T) in subgroup B (TAD/BSA > 21 mm/m2)
Number of subjects: 167

Group type: COMPARATOR
Intervention: No tricuspid regurgitation treatment (group no-T) in subgroup B (TAD/BSA > 21 mm/m2)
Number of subjects: 167
Study: 19543102

Group type: EXPERIMENTAL
Intervention: Viewing humorous films
Number of subjects: 24

Group type: COMPARATOR
Intervention: Viewing control nonhumorous films
Number of subjects: 24
Study: 18412823

Group type: EXPERIMENTAL
Intervention: Multiple-family group intervention (Coffee and Families Education and Support)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Multiple-family group intervention
Number of subjects: 197
Study: 16162882

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12567343

Group type: EXPERIMENTAL
Intervention: Peribulbar block
Number of subjects: 85

Group type: COMPARATOR
Intervention: Intravenous meperidine 1 mg/kg
Number of subjects: 85
Study: 10603722

Group type: EXPERIMENTAL
Intervention: Leprosy patients with facial nerve involvement
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Leprosy patients without facial nerve involvement
Number of subjects: 3

Group type: COMPARATOR
Intervention: Non‐leprosy controls
Number of subjects: 3
Study: 7724097

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 2325569

Group type: EXPERIMENTAL
Intervention: Rocaltrol 0.25 micrograms twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6269476

Group type: EXPERIMENTAL
Intervention: Trimethoprim and polymyxin B (TP)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Trimethoprim, sulphacetamide and polymyxin B (TSP)
Number of subjects: 68
Study: 31023259

Group type: EXPERIMENTAL
Intervention: Bilateral violence
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Unilateral victimization
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Unilateral perpetration
Number of subjects: 930
Study: 28971360

Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 36
Study: 25851423

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 59
Study: 23824103

Group type: EXPERIMENTAL
Intervention: Salvage pulsed-dose-rate brachytherapy (PDR-BT)
Number of subjects: 18
Study: 22089721

Group type: EXPERIMENTAL
Intervention: Very low-normal SBP (<120 mm Hg)
Number of subjects: 20330

Group type: EXPERIMENTAL
Intervention: Low-normal SBP (120-<130 mm Hg)
Number of subjects: 20330

Group type: COMPARATOR
Intervention: High-normal SBP (130-<140 mm Hg)
Number of subjects: 20330

Group type: EXPERIMENTAL
Intervention: High SBP (140-<150 mm Hg)
Number of subjects: 20330

Group type: EXPERIMENTAL
Intervention: Very high SBP (≥150 mm Hg)
Number of subjects: 20330
Study: 19148936

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No inhaled nitric oxide (no iNO)
Number of subjects: 30
Study: 17335364

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (SRP) with azithromycin administered orally 3 days before SRP
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional SRP (Control group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (SRP) with azithromycin
Number of subjects: 34
Study: 15377354

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aldara excipient
Number of subjects: 30
Study: 11164856

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 1200 mg/day for 30 days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 11271904

Group type: EXPERIMENTAL
Intervention: 2% carbogen gas mixture
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 3.5% carbogen gas mixture
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 5% carbogen gas mixture
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control gas
Number of subjects: 14
Study: 9182112

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 500 mg bid
Number of subjects: 162

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate 500 mg/125 mg tid
Number of subjects: 162
Study: 1514154

Group type: EXPERIMENTAL
Intervention: ECG guided percutaneous CVC placement
Number of subjects: 34

Group type: COMPARATOR
Intervention: Blind percutaneous CVC placement (Control)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intraoperative ECG guided CVC placement
Number of subjects: 34
Study: 6637720

Group type: EXPERIMENTAL
Intervention: Standard instruction with uncaptioned videocassette signed by an interpreter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard instruction with captioned videocassette
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard instruction through signed instruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard 4-hour course for non-deaf group
Number of subjects: 0
Study: 31507059

Group type: EXPERIMENTAL
Intervention: Propensity Score Analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Analysis of Covariance (ANCOVA)
Number of subjects: 0
Study: 29393261

Group type: EXPERIMENTAL
Intervention: NEC-surgical
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: NEC-medical
Number of subjects: 133

Group type: COMPARATOR
Intervention: Reference
Number of subjects: 133
Study: 26684170

Group type: EXPERIMENTAL
Intervention: Haptoglobin 2‐2 genotype
Number of subjects: 486

Group type: COMPARATOR
Intervention: Haptoglobin 1 genotype
Number of subjects: 486
Study: 24933726

Group type: EXPERIMENTAL
Intervention: PTSD
Number of subjects: 302

Group type: COMPARATOR
Intervention: No PTSD
Number of subjects: 302
Study: 22617188

Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 0
Study: 20926948

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/day with standard conventional therapy (n=55)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional therapy (n=55)
Number of subjects: 110
Study: 18580172

Group type: EXPERIMENTAL
Intervention: Laryngeal Tube Suction II (LTSII)
Number of subjects: 100

Group type: COMPARATOR
Intervention: ProSeal Laryngeal Mask Airway (PLMA)
Number of subjects: 100
Study: 16083709

Group type: EXPERIMENTAL
Intervention: Peginterferon-alpha-2a (180 microg/wk) plus ribavirin (800-1200 mg/day) for 16 weeks (group A)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Peginterferon-alpha-2a (180 microg/wk) plus ribavirin (800-1200 mg/day) for 24 weeks (group B)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Peginterferon-alpha-2a (180 microg/wk) plus ribavirin (800-1200 mg/day) for 24 weeks (group C)
Number of subjects: 153

Group type: COMPARATOR
Intervention: HCV-3 patients with high viral load (>800,000 IU/mL)
Number of subjects: 153

Group type: COMPARATOR
Intervention: HCV-3 patients with low viral load (≤800,000 IU/mL)
Number of subjects: 153
Study: 12096200

Group type: EXPERIMENTAL
Intervention: nNO in PCD
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: eNO in PCD
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: nNO diagnostic use
Number of subjects: 157

Group type: COMPARATOR
Intervention: nNO in Bx
Number of subjects: 157

Group type: COMPARATOR
Intervention: nNO in CF
Number of subjects: 157

Group type: COMPARATOR
Intervention: nNO in A
Number of subjects: 157

Group type: COMPARATOR
Intervention: nNO in C
Number of subjects: 157

Group type: COMPARATOR
Intervention: eNO in Bx
Number of subjects: 157

Group type: COMPARATOR
Intervention: eNO in CF
Number of subjects: 157

Group type: COMPARATOR
Intervention: eNO in A
Number of subjects: 157

Group type: COMPARATOR
Intervention: eNO in C
Number of subjects: 157
Study: 10601131

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 to 40 mg/d)
Number of subjects: 30
Study: 8543490

Group type: EXPERIMENTAL
Intervention: iv meropenem (1 g every 8 h)
Number of subjects: 237

Group type: COMPARATOR
Intervention: iv ceftazidime (2 g every 8 h) plus iv amikacin (15 mg/kg/day in two or three divided doses)
Number of subjects: 237
Study: 2024812

Group type: EXPERIMENTAL
Intervention: Colchicine (0.6 mg three times per day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29982294

Group type: COMPARATOR
Intervention: EX (aerobic training; treadmill 4 days/week for 30 minutes at 65%-70% of heart rate reserve)
Number of subjects: 180

Group type: COMPARATOR
Intervention: EX + Mod-CR (aerobic training with moderate caloric restriction -250 kcal/d)
Number of subjects: 180

Group type: COMPARATOR
Intervention: EX + High-CR (aerobic training with high caloric restriction -600 kcal/d)
Number of subjects: 180
Study: 29523194

Group type: EXPERIMENTAL
Intervention: Chlorhexidine solution umbilical cord cleansing regimen
Number of subjects: 30267

Group type: COMPARATOR
Intervention: Previous child death in the family
Number of subjects: 30267

Group type: COMPARATOR
Intervention: Overcrowding
Number of subjects: 30267

Group type: COMPARATOR
Intervention: Home delivery
Number of subjects: 30267

Group type: COMPARATOR
Intervention: Unclean cord care
Number of subjects: 30267

Group type: COMPARATOR
Intervention: Multiple births
Number of subjects: 30267

Group type: COMPARATOR
Intervention: Low birth weight
Number of subjects: 30267

Group type: COMPARATOR
Intervention: Birth asphyxia
Number of subjects: 30267

Group type: COMPARATOR
Intervention: Higher pregnancy order
Number of subjects: 30267
Study: 25911347

Group type: EXPERIMENTAL
Intervention: Parents Plus‐Parenting when Separated Programme
Number of subjects: 82

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 82
Study: 24692535

Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning (RIPost) induced by ischemia to the arm
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning (RIPost) induced by ischemia to the thigh
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group (20 mm Hg blood pressure cuff inflation)
Number of subjects: 360
Study: 22564993

Group type: EXPERIMENTAL
Intervention: metformin 850 mg/twice per day
Number of subjects: 200

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 200
Study: 20417906

Group type: EXPERIMENTAL
Intervention: Charnley stem with Charnley cup
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Charnley stem with uncemented hemispherical cup (Duraloc)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Any revisions as endpoint
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Charnley stem
Number of subjects: 240
Study: 17413694

Group type: EXPERIMENTAL
Intervention: Nevirapine cessation
Number of subjects: 19
Study: 16568708

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with Der p 1 standardized allergens (total dose of 10,469 UBE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with Der p 1 standardized allergens
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12111069

Group type: EXPERIMENTAL
Intervention: Percutaneous cholecystostomy (PC)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Conservative treatment (CO)
Number of subjects: 123
Study: 10390703

Group type: EXPERIMENTAL
Intervention: Hemp seed tea (12 ounces)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hemp seed tea (24 ounces)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo tea (12 ounces)
Number of subjects: 22
Study: 7760242

Group type: EXPERIMENTAL
Intervention: Group A: 10.0 g/kg/d of dextrose and 4.0 g/kg/d of fat
Number of subjects: 14

Group type: COMPARATOR
Intervention: Group B: 19.0 g/kg/d of dextrose and 0.5 g/kg/d of fat
Number of subjects: 14
Study: 2269143

Group type: EXPERIMENTAL
Intervention: Occlusal splints with large 'a' (radius of the maximal curvature of the sagittal anterior tooth curvature)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Occlusal splints with small 'a'
Number of subjects: 12
Study: 6155987

Group type: EXPERIMENTAL
Intervention: MOPP/ABDV
Number of subjects: 84
Study: 31996253

Group type: EXPERIMENTAL
Intervention: Good maternal growth monitoring knowledge
Number of subjects: 340

Group type: COMPARATOR
Intervention: Poor maternal growth monitoring knowledge
Number of subjects: 340
Study: 31801725

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 648

Group type: COMPARATOR
Intervention: Standard practice (control group)
Number of subjects: 648
Study: 28993164

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 30 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 200
Study: 26022762

Group type: EXPERIMENTAL
Intervention: BMSC therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 24590053

Group type: COMPARATOR
Intervention: Blue light/placebo (BLU)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: White light/240‐mg caffeine (CAF)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Blue light/240‐mg caffeine (BCAF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: White light/placebo (PLA)
Number of subjects: 20
Study: 22594651

Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes plus usual Quitline care (8 weeks of NRT patches and/or gum or lozenges, plus behavioural support)
Number of subjects: 1410

Group type: COMPARATOR
Intervention: Usual Quitline care alone
Number of subjects: 1410
Study: 18678424

Group type: EXPERIMENTAL
Intervention: Anteroposterior electrode position (Group B)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Anterolateral electrode position (Group A)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 16178829

Group type: EXPERIMENTAL
Intervention: Patients who received a letter about medical education (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients who did not receive a letter (control group)
Number of subjects: 0
Study: 12850610

Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg per day
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg per day
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 10462244

Group type: EXPERIMENTAL
Intervention: Meningococcal A/C polysaccharide vaccine (MPS)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Meningococcal A/C conjugate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Inactivated polio vaccine (IPV)
Number of subjects: 42
Study: 8857079

Group type: EXPERIMENTAL
Intervention: Oral administration of 12 mmol magnesium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of 24 mmol magnesium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 4 mmol magnesium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 8 mmol magnesium
Number of subjects: 0
Study: 1676027

Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate
Number of subjects: 1549

Group type: COMPARATOR
Intervention: Control (suspected viral infections)
Number of subjects: 1549
Study: 6809470

Group type: EXPERIMENTAL
Intervention: Alucol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Camalox
Number of subjects: 10
Study: 31910279

Group type: EXPERIMENTAL
Intervention: Folic acid and zinc supplementation (5 mg of folic acid and 30 mg of elemental zinc daily for 6 months)
Number of subjects: 2370

Group type: COMPARATOR
Intervention: Placebo (daily for 6 months)
Number of subjects: 2370

Group type: EXPERIMENTAL
Intervention: Folic acid and zinc supplementation
Number of subjects: 2370

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2370
Study: 31291989

Group type: EXPERIMENTAL
Intervention: Tailored insight visual support strategies
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 100
Study: 28679140

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU every 2 weeks for 12 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 25615911

Group type: EXPERIMENTAL
Intervention: Social exclusion condition (Cyberball paradigm)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Control condition (Cyberball paradigm)
Number of subjects: 299
Study: 23837141

Group type: EXPERIMENTAL
Intervention: Entecavir plus carnitine complex (GODEX®)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Entecavir monotherapy
Number of subjects: 130
Study: 22084369

Group type: EXPERIMENTAL
Intervention: Presence of small-cell (SC) or lymphohistiocytic (LH) component
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Perivascular pattern
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: CD3 positivity
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Histologic subtyping concordance
Number of subjects: 375
Study: 18682741

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (aspirin, clopidogrel, dipyridamole)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 17
Study: 16484270

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 15853508

Group type: EXPERIMENTAL
Intervention: Nonpharmacological interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonpharmacological and pharmacological interventions
Number of subjects: 0
Study: 11300575

Group type: EXPERIMENTAL
Intervention: Low-level construals
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-level construals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decreased temporal distance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aversion to inconvenience
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Approach-avoidance conflict
Number of subjects: 0
Study: 9391254

Group type: EXPERIMENTAL
Intervention: Intravenous octreotide (50 pg/h for 48 hours)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Emergency sclerotherapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intravenous octreotide
Number of subjects: 150
Study: 7944837

Group type: EXPERIMENTAL
Intervention: Glycosylated hemoglobin levels in the highest quartile at baseline (younger-onset group)
Number of subjects: 1516

Group type: EXPERIMENTAL
Intervention: Glycosylated hemoglobin levels in the highest quartile at baseline (older-onset group taking insulin)
Number of subjects: 1516

Group type: EXPERIMENTAL
Intervention: Glycosylated hemoglobin levels in the highest quartile at baseline (older-onset group not taking insulin)
Number of subjects: 1516